Agent(s) | No. Patients (%), Total = 176 |
---|---|
Adalimumab | 46 (26.1) |
Adalimumab + MTX | 16 (9.1) |
Adalimumab + leflunomide | 2 (1.1) |
Adalimumab + infliximab* | 1 (0.6) |
Adalimumab + MTX + HCQ | 2 (1.1) |
Etanercept | 37 (21.0) |
Etanercept + MTX | 21 (11.9) |
Etanercept + leflunomide | 2 (1.1) |
Etanercept + HCQ | 1 (0.6) |
Etanercept + sulfasalazine | 1 (0.6) |
Etanercept + MTX + HCQ | 2 (1.1) |
Etanercept + MTX + sulfasalazine | 1 (0.6) |
Abatacept | 17 (9.7) |
Abatacept + MTX | 7 (4.0) |
Abatacept + MTX + HCQ | 2 (1.1) |
Infliximab* | 10 (5.7) |
Infliximab + MTX | 7 (4.0) |
Infliximab + leflunomide | 1 (0.6) |
↵* protocol deviation. MTX: methotrexate; HCQ: hydroxychloroquine.